# US 2019/0316093 A1 · Screenable liver disease models and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316093 A1
- Document ID: US20190316093A1
- Status: Published application
- Kind: A1
- Application number: 16/471,551
- Filed: 2017-12-27
- Published: 2019-10-17
- Earliest claimed: 2016-12-23
- Applicants: Insphero AG
- Inventors: Simon Messner; Jens M. Kelm; Radina Kostadinova-Angelova; Wolfgang Moritz
- Web page: https://patentgrep.com/patent/US20190316093A1

## CPC

- C12N 5/0671: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- C12N 5/0062: {General methods for three-dimensional culture}
- C12N 5/0697: {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N5/0691)}
- G01N 33/5067: {Liver cells}
- G01N 33/5088: {of vertebrates}
- C12N 2502/1157: Monocytes, macrophages
- C12N 2502/28: Vascular endothelial cells
- C12N 2503/04: Screening or testing on artificial tissues
- C12N 2513/00: 3D culture
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to an in vitro testing platform for the study of metabolic liver disease and related therapeutic strategies, composed of an artificial spheroidal microtissue comprising at least hepatocytes and hepatic stellate cells, and at least one type of hepatic inflammatory cells and further medium and reagents capable to establish and simulate different stages of metabolic liver disease and their progression and testing preventive and therapeutic strategies by pharmacological and/or dietary interventions.

## Claims

### Claim 1

An artificial spheroidal microtissue comprising at least hepatocytes and hepatic stellate cells, and further at least one type of hepatic inflammatory cells.

### Claim 2 (depends on 1)

The artificial spheroidal microtissue according to claim 1, wherein the hepatic inflammatory cells are Kupffer cells.

### Claim 3 (depends on 1, 2)

The artificial spheroidal microtissue according to claim 1 or 2, which microtissue further comprises endothelial cells.

### Claim 4 (depends on 1, 2, 3)

The artificial spheroidal microtissue according to any one of claims 1-3, which microtissue has a diameter of between ≥30 μm and ≤500 μm.

### Claim 5 (depends on 1, 2, 3, 4)

The artificial spheroidal microtissue according to any one of claims 1-4, which microtissue comprises between ≥500 and ≤10000 cells in total.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The artificial spheroidal microtissue according to any one of claims 1-5, wherein the sinusoidal endothelial cells form a cell layer around the three dimensional microtissue comprising at the remaining cell types.

### Claim 7

The artificial spheroidal microtissue according to any one of the aforementioned claims, in which microtissue the cells are mammalian cells, preferably selected from the group consisting of
human cells
monkey cells
pig cells
canine cells, and/or
rodent cells.

### Claim 8

The artificial spheroidal microtissue according to any one of the aforementioned claims, wherein
a) the microtissue comprises pro-activated stellate cells, and/or
b) the microtissue represents a liver model at basal state.

### Claim 9 (depends on 8)

The artificial spheroidal microtissue according to claim 8b, wherein the microtissue is progressed to at one of the states selected from the list consisting of:
a) insulin resistant state,
b) steatotic state,
c) inflammatory state,
d) fibrotic state,
e) NASH/Fibrosis phenotype, option 1,
f) NASH/Fibrosis phenotype, option 2.

### Claim 10

A method of preparing a spheroidal microtissue comprising at least hepatocytes, hepatic stellate cells, hepatic inflammatory cells, and further endothelial cells, which method comprises the steps of
a) producing or providing a microtissue comprising at least hepatocytes, hepatic stellate cells and hepatic inflammatory cells,
b) producing or providing a suspension comprising sinusoidal endothelial cells,
c) dispensing said suspension into wells or vessels comprising one or more microtissues of step a)
d) incubating said wells or vessels to let sinusoidal endothelial cells adhere to the microtissues

### Claim 11 (depends on 10)

The method according to claim 10, in which method the microtissues are grown and cultivated in a hanging drop system.

### Claim 12 (depends on 10)

The method according to claim 10, in which method the microtissues are grown and cultivated in a low adherence well.

### Claim 13 (depends on 10, 11, 12)

The method according to any one of claims 10-12, in which method at least some of the cells are cryopreserved cells which are thawed before processing.

### Claim 14 (depends on 10, 11, 12)

The method according to any one of claims 10-12, in which method at least some of the cells are non-frozen cells.

### Claim 15 (depends on 10, 11, 12, 13, 14)

A spheroidal microtissue that has been obtained with a method according to any one of claims 10-14.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 15)

A model platform for liver disease modelling, said model platform comprising a microtissue according to any one of claims 1-9 and 15

### Claim 17 (depends on 16)

The model platform according to claim 16, which model platform allows at least one selected from the group consisting of;
mechanistic studies of disease progression,
prevention of disease progression by pharmacological or dietary intervention, and/or
the reversion of diseased states.

### Claim 18 (depends on 16, 17)

The model platform according to any one of claims 16-17, further being provided in an assay-ready format composed of basic media and reagents enabling the installment and recapitulation of disease specific states, representative of specific preventive and therapeutic entry points.

### Claim 19 (depends on 18)

The model platform according to claim 18, wherein the platform further comprises quality-control data and calibration data, which data are specific to the production batch, and provide information about at least one feature selected from the group consisting of:
Biomarkers for disease progression,
Cell viability and functionality, and/or
Microtissue size.

### Claim 20 (depends on 16, 17, 18, 19)

The model platform according to any one of claims 16-19, wherein the liver disease is at least one selected from the group consisting of:
liver fibrosis,
viral hepatitis (e.g., hepatitis B and C),
alcoholic or obesity-associated steatohepatitis (e.g., nonalcoholic steatohepatitis (NASH)),
parasitic disease (e.g., schistosomiasis),
metabolic disorders (e.g., Wilson's),
hemochromatosis and other storage diseases,
congenital abnormality,
autoimmune and chronic inflammatory conditions (e.g., sarcoidosis), and/or
drug toxicity.

### Claim 21 (depends on 16, 17, 18, 19, 20)

The model platform according to any one of claims 16-20, wherein the spheroidal microtissue is in co-culture with at least one type of inflammatory cells.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A liver fibrosis model which has been obtained with a method according to any one of claims 10-14 and/or comprises a spheroidal microtissue according to any one of claim 1-9 or 15 and/or comprises a platform according to any one of claims 16-21.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

An assay method for testing compounds
suspected for promoting, causing, or increasing the risk of NAFLD/NASH/Fibrosis, or
for their potency to reduce the risk, alleviate the symptoms, treat the causes of NAFLD/NASH/Fibrosis or to reverse the pathological states of NAFLD/NASH/Fibrosis,
in a spheroidal microtissue according to any according to claim 1-9 or 15, or being obtained with a method according to any one of claims 10-14, and/or comprising a platform according to any one of claims 16-21,
which method comprises the steps of
a) treatment of one or more test microtissues with one or more test compounds suspected for promoting, causing, or increasing the risk of, NAFLD/NASH/Fibrosis, and
b) parallel or subsequent treatment with one or more test compounds intended to reverse NAFLD/NASH/Fibrosis
c) carrying out an endpoint analysis of at least one genetic, physiologic and/or morphologic parameter relevant to the respective liver pathology.

### Claim 24 (depends on 23)

The method according to claim 23, in which method a positive control is furthermore used, which positive control comprises:
a′) treatment of a control microtissue with a control agent selected from a group of fibrosis inducers (e.g. TGF-β1), steatosis inducers (e.g. cholesterol, fatty acids) and/or inflammation inducers (e.g. TNF-α, Lipopolysaccharide)
b′) carrying out the same endpoint analysis of at least one genetic, physiologic and/morphologic parameter, and

### Claim 25 (depends on 23, 24)

The method according to any one of claims 23-24, wherein the endpoint analysis refers to at least one parameter selected from the group consisting of:
Release of one or more biomarkers
Lipid content of the microtissue cells
Histology of the microtissue and its cells (disrupted/non disrupted)
RNA expression marker such as alpha-smooth muscle actin, COL1A1, Vimentin or TIMP-1
Size or volume of the microtissue, and/or
Mitochondrial activity

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

Use of a spheroidal microtissue according to claim 1-9 or 15, or obtained with a method according to any one of claims 10-14, or of a platform according any one of claims 16-21, for at least one purpose selected from the group consisting of:
drug efficacy and/or toxicity screenings,
investigative/mechanistic toxicology,
target discovery/identification,
drug repositioning studies, and/or
pharmacokinetics and pharmacodynamics assays.
